TOG Review (RCOG Journal)

MRCOG Part 2

Urogynaecology and Pelvic Floor Problems

Vaginal mesh in prolapse surgery

Key Statistics

  • 46% vs 18% — Anatomic failure: Biological vs synthetic mesh (p=0.015)
  • 15.8% — Lifetime risk repeat POP surgery (UK, n=47,000)
  • 12% — Mesh complication rate at 2yr, PROSPECT (n=1352)

Don't-miss facts

  1. Only Type 1 macroporous (>75 µm) monofilament polypropylene mesh is used for current POP repair (Amid classification)

  2. ProteGen® (1996) approved via FDA 510(k) pathway without dedicated transvaginal safety trials – root of the regulatory controversy

  3. FDA reclassified transvaginal POP mesh class II→III in Jan 2016 after declaring adverse events “not rare” (2011)

  4. Maher 2016 Cochrane (37 RCTs): mesh ↓recurrence but ↑combined repeat surgery (RR 2.40), ↑de novo SUI (RR 1.39), ↑bladder injury (RR 3.92) – no evidence to support routine use

  5. PROSPECT (n=1352): no benefit from mesh/graft augmentation of primary repair at 1–2yr; synthetic mesh complications 12% at 2yr

  6. Biological mesh: significantly higher anatomic failure than synthetic mesh (46% vs 18%, P=0.015)

  7. UK lifetime risk of repeat POP surgery after native tissue repair = 15.8% (lower than the 30–50% historically quoted)

  8. Informed consent (shared decision making) is the key ethical issue; mesh use carries greater litigation risk than native tissue repair

Evidence & regulatory timeline

1996: FDA 510(k) approval (ProteGen®) 2011: FDA – adverse events “not rare” 2016: class II→III reclassification

2017: PROSPECT – no benefit at 1–2yr

Abbreviation Key

  • POP — pelvic organ prolapse
  • PROSPECT — PROlapse Surgery: Pragmatic Evaluation and randomised Controlled Trials
  • SUI — stress urinary incontinence
  • POP-SS — Pelvic Organ Prolapse Symptom Score
  • FDA — US Food and Drug Administration
  • POP-Q — Pelvic Organ Prolapse Quantification system
  • MHRA — Medicines and Healthcare products Regulatory Agency
  • RCT — randomised controlled trial
  • NICE — National Institute for Health and Care Excellence
  • RR — relative risk
  • RCOG — Royal College of Obstetricians and Gynaecologists
  • CI — confidence interval
  • BSUG — British Society of Urogynaecology
  • MAUDE — Manufacturer and User Device Experience database
  • BAUS — British Association of Urological Surgeons
  • GMC — General Medical Council
  • IUGA — International Urogynecological Association
  • HES — hospital episode statistics
  • SCENIHR — Scientific Committee on Emerging and Newly Identified Health Risks

Source: Campbell P, Jha S, Cutner A. Vaginal mesh in prolapse surgery. The Obstetrician & Gynaecologist 2018;20:49–56. doi:10.1111/tog.12454

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free